Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paclitaxel - Angiotech

Next Previous
X
Search
Drug Profile

Paclitaxel - Angiotech

Alternative Names: Cremophor EL-free paclitaxel - Angiotech; Eluvia; Formula PTX; Innova; Micellar paclitaxel; Paxceed; TAXUS Element; TAXUS Express2; TAXUS Liberte; TAXUS Petal; Vascular Wrap; Zilver PTX

Latest Information Update: 11 Aug 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Angiotech Pharmaceuticals
  • Developer Angiotech Pharmaceuticals; Boston Scientific Corporation; Broncus Technologies; Cook Medical
  • Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inhibitors; Immunosuppressants; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary artery restenosis; Myocardial infarction; Vascular restenosis
  • Discontinued Alzheimer's disease; Cancer; Emphysema; Multiple sclerosis; Oesophageal cancer; Post-surgical adhesions; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 15 Apr 2021 Discontinued - Phase-III for Emphysema in Europe, USA (Intrapulmonary)
  • 05 Nov 2019 Efficacy data from the phase III IMPERIAL trial in Vascular restenosis presented at the Vascular InterVentional Advances meeting (VIVA-2019)
  • 24 Sep 2018 The US FDA approves a Premarket Approval application of Eluvia™ Drug-Eluting Vascular Stent System for Peripheral artery disorders

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top